94 results
425
EX-99.3
CELU
Celularity Inc - Ordinary Shares
8 Jan 21
Business combination disclosure
7:02am
High expandability, persistence and stemness x Immunological naivete allows for improved safety profile of therapeutic products HEMATOLOGICAL … Sharmila Koppisetti , MD VP Drug Safety Pharmacovigilance Senior Medical Team Chi Li, PhD, MBA, RAC SVP Regulatory Affairs Robert J. Hariri, MD, PhD Founder
8-K
EX-99.3
CELU
Celularity Inc - Ordinary Shares
8 Jan 21
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
7:03am
High expandability, persistence and stemness x Immunological naivete allows for improved safety profile of therapeutic products HEMATOLOGICAL … Sharmila Koppisetti , MD VP Drug Safety Pharmacovigilance Senior Medical Team Chi Li, PhD, MBA, RAC SVP Regulatory Affairs Robert J. Hariri, MD, PhD Founder
425
CELU
Celularity Inc - Ordinary Shares
11 Feb 21
Business combination disclosure
6:27am
Immunological naivete allows for improved safety profile of therapeutic products HEMATOLOGICAL MALIGNANCIES INFECTIOUS DISEASE DEGENERATIVE DISEASES SOLID TUMORS … Safety Pharmacovigilance Senior Medical Team Chi Li, PhD, MBA, RAC SVP Regulatory Affairs Robert J. Hariri, MD, PhD Founder & CEO John Haines Chief
425
CELU
Celularity Inc - Ordinary Shares
27 Apr 21
Business combination disclosure
8:40pm
for allogeneic therapies ▪ Potential for improved safety profile due to immunological naivety Strong pre - clinical evidence of anti - tumor activity … CyCART - 19 in R/R B - Cell NHL IND submission : 2H 2021 Phase 1 (safety and dose finding) start 2H 2021 Advantages CAR - T THERAPIES Cell Therapy T e
UPLOAD
CELU
Celularity Inc - Ordinary Shares
22 Feb 21
Letter from SEC
12:00am
the graphic on page 168 to delete the reference to placental
based cells allow[ing]
for improved safety profile. Below the graphic, you … LastNameJay R. Bloom
product candidates are safe or effective. Safety and efficacy
determinations are solely
Comapany NameGX
within
425
trdgg fiz9ekpdqb4at
15 Jun 21
Business combination disclosure
12:00am
8-K
EX-99.1
2yyu3zf
17 Jun 22
Other Events
4:57pm
8-K
EX-99.1
yanri0
16 Feb 22
Other Events
8:31am
424B3
1xnrgc2uhx
1 Jun 22
Prospectus supplement
4:06pm
CORRESP
f5fdmm7zwoae1
29 Mar 21
Correspondence with SEC
12:00am
424B3
ne2l40yj
3 May 22
Prospectus supplement
4:06pm
POS AM
6aea0g6oesr h7w
1 Apr 22
Prospectus update (post-effective amendment)
9:15pm
8-K
EX-99.1
3qebucd6c0w4jv
18 Jan 22
Other Events
4:06pm
424B3
yaxsmsfo8vzwx
12 Aug 21
Prospectus supplement
4:21pm